Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study

血管抑制剂 医学 自然科学 视网膜分支静脉阻塞 眼科 视力 黄斑水肿 置信区间 养生 视网膜 随机对照试验 外科 内科学 贝伐单抗 化疗
作者
Wenbin Wei,Annemarie Weisberger,Liansheng Zhu,Yu Cheng,Chang Liu
出处
期刊:Ophthalmology Retina [Elsevier BV]
卷期号:4 (1): 57-66 被引量:23
标识
DOI:10.1016/j.oret.2019.08.001
摘要

To assess the efficacy and safety profile of intravitreal ranibizumab 0.5 mg in Asian patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). A 12-month, phase III, double-masked study. A total of 283 patients with BRVO. Patients aged ≥18 years were randomized (2:1) to receive ranibizumab 0.5 mg or sham. The ranibizumab group received a minimum of 3 monthly intravitreal injections until stable maximal visual acuity (VA) was achieved followed by an individualized VA stabilization criteria–driven pro re nata (PRN) regimen. Patients in the sham group received sham injections up to month 5 and could receive ranibizumab 0.5 mg PRN from month 6. Mean average change in best-corrected VA (BCVA) from baseline to month 1 through month 6 and safety up to month 12. At baseline, patients’ mean (standard deviation [SD]) BCVA and central subfield thickness (CSFT) were 57.4 (11.7) letters and 525 (193.4) μm, respectively. Compared with sham, ranibizumab treatment resulted in superior VA gains. The least squares (LS) mean average change in BCVA from baseline to month 1 to month 6 in ranibizumab and sham groups was +12.5 and +5.0 letters, respectively (LS mean difference between ranibizumab vs. sham: +7.5 letters [95% confidence interval, 5.5–9.5], 1-sided P < 0.001). The LS mean change from baseline at month 12 in the ranibizumab versus sham groups in BCVA was +16.4 (14.9–17.8) versus +11.4 (9.3–13.5) letters and in CSFT was −280.0 (−291.6 to −268.4) versus −269.7 (−286.2 to −253.1) μm. The mean (SD) number of injections over 12 months was 7.0 (2.55) in the ranibizumab group and 3.6 (1.60) in the sham with ranibizumab group. No new safety findings were reported. In Asian patients with BRVO, individualized PRN ranibizumab treatment was statistically superior to sham at month 6 and led to early visual gains that were maintained up to 12 months. Results from the sham group indicate the importance of early treatment in achieving optimal visual outcomes in BRVO. The safety of ranibizumab in this study was consistent with the well-established safety profile of ranibizumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HH完成签到 ,获得积分10
刚刚
1秒前
丘比特的应助被程风破浪采纳,获得10
1秒前
und发布了新的文献求助50
2秒前
2秒前
明天剪纸发布了新的文献求助10
2秒前
万能图书馆的应助被22x采纳,获得10
3秒前
3秒前
月见黑完成签到,获得积分10
3秒前
4秒前
豆豆完成签到,获得积分10
4秒前
归尘发布了新的文献求助10
5秒前
6秒前
nandiaozhimu完成签到,获得积分10
6秒前
6秒前
7秒前
羔羔羊发布了新的文献求助10
7秒前
心心子完成签到 ,获得积分10
7秒前
7秒前
苹果大王完成签到 ,获得积分10
8秒前
8秒前
8秒前
8秒前
冠心没有病完成签到,获得积分10
11秒前
whoare发布了新的文献求助10
11秒前
13秒前
小二郎的应助被呆小仙采纳,获得10
14秒前
科研通AI6.2的应助被SJJ采纳,获得10
14秒前
xx发布了新的文献求助10
15秒前
脑洞疼的应助被xueee采纳,获得10
15秒前
曾许京城第一流完成签到,获得积分10
16秒前
科研通AI6.2的应助被Aniya采纳,获得10
17秒前
学术混子完成签到,获得积分10
18秒前
周澍完成签到,获得积分10
19秒前
link完成签到 ,获得积分10
19秒前
19秒前
20秒前
Garcia完成签到,获得积分10
20秒前
秋枫冬雪完成签到,获得积分10
20秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153509
求助须知:如何正确求助?哪些是违规求助? 9550216
关于积分的说明 21697167
捐赠科研通 7742065
什么是DOI,文献DOI怎么找? 3425525
关于科研通互助平台的介绍 2550636
邀请新用户注册赠送积分活动 2469175